Daniel Serrano

University of Colorado System

H指数:36

被引数:8,305

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Psychometric validation of the PROMIS Fatigue-Short Form 7a in adults with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease: the ARISE and ENCORE studies

PROMIS疲劳简表7a在 newly diagnosed 或 recurrent Mycobacterium avium complex (MAC) 肺病患者中的心理测量学验证：ARISE 和 ENCORE 研究

JOURNAL OF PATIENT-REPORTED OUTCOMES

IF2.9

2025-10-160

Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305

基于患者报告结局（PRO）的反复症状性恶化可预测无进展生存期（PFS）：RATIONALE-305研究的结果

ANNALS OF ONCOLOGY

IF65.4

2024-09-010

PRE

Immune profiling of dedifferentiated liposarcoma and identification of novel antigens for targeted immunotherapy

SCIENTIFIC REPORTS

IF3.9

2024-05-163

OAAI

Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE

NEUROLOGY AND THERAPY

IF4.8

2023-11-015

OAAI

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVA51 oncolytic virotherapy

MOLECULAR THERAPY

IF12

2023-11-017

OAAI

Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials

HEADACHE

IF4

2023-10-240

OAAI

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

JOURNAL OF HEADACHE AND PAIN

IF7.9

2023-08-039

OAAI

Treatment Effects of Celecoxib Oral Solution in Migraine With Aura and Without Aura: Post-Hoc Analysis of Results From Two Randomized, Double-Blind Placebo-Controlled Trials

NEUROLOGY

IF8.5

2023-04-250

PRE

Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-11-285

OAAI

Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple Myeloma

VALUE IN HEALTH

IF6

2021-12-014

PREAI

Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma

QUALITY OF LIFE RESEARCH

IF2.7

2021-09-132

OAAI

Validation of the Ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis

强直性脊柱炎生活质量评估工具在非影像学中轴脊柱关节炎患者中的验证

QUALITY OF LIFE RESEARCH

IF2.7

2020-10-3113

OAAI

Dysregulated liver lipid metabolism and innate immunity associated with hepatic steatosis in neonatal BBdp rats and NOD mice

SCIENTIFIC REPORTS

IF3.9

2019-10-100

OAAI

A psychometric analysis and revalidation of the Yale-Brown Obsessive Compulsive Scale modified for Binge Eating in adults with binge eating disorder

Yale-Brown强迫症量表的心理测量分析和重新验证，用于成人暴食症的暴饮暴食

QUALITY OF LIFE RESEARCH

IF2.7

2019-08-318

OAAI

UNBIASED TREATMENT EFFICACY DETECTION METHODS WHEN USING PATIENT REPORTED OUTCOMES IN SURVIVAL-DEPENDENT DROP-OUT

VALUE IN HEALTH

IF6

2019-05-010

OAAI

A NEWLY DEVELOPED POWER PROCEDURE FOR SAMPLE SIZE PLANNING IN COA VALIDATION STUDIES

VALUE IN HEALTH

IF6

2019-05-010

OAAI

Measurement properties of the Fabry Disease Patient Reported Outcome (FD-PRO), a new instrument to measure symptoms in Fabry disease

MOLECULAR GENETICS AND METABOLISM

IF3.5

2019-02-011

PREAI

Changes in insulin, glucagon and ER stress precede immune activation in type 1 diabetes

JOURNAL OF ENDOCRINOLOGY

IF3.9

2018-11-018

OAAI

Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches

NEUROLOGY AND THERAPY

IF4.8

2018-04-023

OAAI

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design

1年内发作性和慢性偏头痛状态的波动: 对诊断，治疗和临床试验设计的影响

JOURNAL OF HEADACHE AND PAIN

IF7.9

2017-10-04162

OAAI

Daniel Serrano

个人简介

教育背景

工作经历

荣誉奖项

研究方向